Lytispasm en es it fr

Lytispasm Brand names, Lytispasm Analogs

Lytispasm Brand Names Mixture

  • No information avaliable

Lytispasm Chemical_Formula


Lytispasm RX_link

No information avaliable

Lytispasm fda sheet

Lytispasm msds (material safety sheet)

Lytispasm Synthesis Reference

No information avaliable

Lytispasm Molecular Weight

362.346 g/mol

Lytispasm Melting Point

329 oC

Lytispasm H2O Solubility

1600 mg/L

Lytispasm State


Lytispasm LogP


Lytispasm Dosage Forms

Tablet (oral, 50mg)

Lytispasm Indication

For use in conjunction with antacids or histamine H2-receptor antagonists in the treatment of peptic ulcer, to reduce further gastric acid secretion and delay gastric emptying.

Lytispasm Pharmacology

Anisotropine methylbromide is a quaternary ammonium compound. Its use as treatment adjunct in peptic ulcer has been replaced by the use of more effective agents. Depending on the dose, anisotropine methylbromide may reduce the motility and secretory activity of the gastrointestinal system, and the tone of the ureter and urinary bladder and may have a slight relaxant action on the bile ducts and gallbladder. In general, smaller doses of anisotropine methylbromide inhibit salivary and bronchial secretions, sweating, and accommodation; cause dilatation of the pupil; and increase the heart rate. Larger doses are required to decrease motility of the gastrointestinal and urinary tracts and to inhibit gastric acid secretion.

Lytispasm Absorption

Gastrointestinal absorption is poor and irregular. Total absorption after an oral dose is about 10 to 25%.

Lytispasm side effects and Toxicity

No information avaliable

Lytispasm Patient Information

Lytispasm Organisms Affected

Humans and other mammals